Donald Trump's three-days-recovery ascertains biotech firms about the effectiveness of the treatment and accelerates the production for the global market.
When US President Donald Trump boarded the Marine One helicopter, which would take him to hospital, doctors knew that he is in life-threatening condition. In the morning, Mr. Trump received oxygen to soften his symptoms, including coughing. President’s Chief of Staff Mark Meadows later would tell journalists: “The president’s vitals over the last 24 hours were very concerning, and the next 48 hours will be critical in terms of his care,” he said. “We’re still not on a clear path to a full recovery.”
On Friday night, after examination of President Trump, the doctors at the Walter Reed Medical Center decided to treat him with an experimental drug. He received a single, 8-gram dose of Regeneron’s polyclonal antibody cocktail, which consists of blood samples, stated Navy Commander Dr. Sean Conley.
After it turned out that the President test was positive, US biotechnology firm Regeron requested Singapore’s National Centre for Infectious Diseases to recruit up to 20 recovered patients for the contribution of samples.
After obtaining ethics approval and informed consent of patients, NCID recruited five patients and was informed by Regeneron that they had - at that point - sufficient samples to develop the antibody cocktails, Associate Professor David Lye, senior consultant, and director of the Infectious Disease Research and Training Office at NCID. Regeneron used three of the five Singapore patient samples as the research starting point to develop the antibodies.
At the time when President Trump received the treatment, the drug was still in clinical trials. But Dr. David Nace, chief medical officer of UPMC Senior Communities in Pittsburgh, USA, stated results were encouraging.
The experimental treatment does not involve the destruction of human life
Regeneron's treatment, called REGN-COV2, is a combination, or "cocktail" of two antibodies, which are infection-fighting proteins that were developed to bind themselves to the virus and inhibit it from invading human cells.
Unlike some US doctors, with pro-Democratic sentiments, claimed the drug does not contain the cells from aborted human persons.
No human cells from abortion are being used in the production of the Regeneron treatment.
The president was not given any medicines to treat COVID-19 that involved the destruction of human life. No human embryonic stem cells or human fetal tissue were used to produce the treatments President Trump received–period, stated Drs David Prentice, Ph.D and Tara Sander Lee, Ph.D., of the US Charlotte Lozier Institute.
The drug contains antibodies made from Velocimmune mice and blood from recovered patients previously infected with SARS-CoV-2. The final antibody pair used in the REGN-COV2 therapy cocktail was then produced in Chinese hamster ovary (CHO) cells.
President Trump obtained the drug through a compassionate use request, which the U.S. Food and Drug Administration describes as a way for a patient with an immediately life-threatening condition or serious disease to get a treatment still in trials when no alternative therapies are available.
No doubt the doctors informed Mr Trump the treatment could cause side effects that would complicate his condition. But it did not stop him from taking the drug. He took a risk.
Mr Trump recovered in three days to the disbelief of his political opponents. Under-informed Speaker of the House even tried to launched the procedure to remove the President from his office even though the doctors said he was healthy.
She did not know that the treatment is a game-changer, stated retired high official at a US Military Research Biotech Center Dr John Simpson. The recovery paves the way for the fast-approval of this type treatments against the Wuhan virus, he stated in an interview with The Owner.
US President's Treatment Results Ascertain Developers
The international pharmaceutical community has no doubt that the fast recovery of President Trump thanks to the experimental drugs has accelerated production of the Regeneron treatment and development of other promising drug. On Friday, the United States signed with pharmaceutical firm Astra-Zeneca contract on the manufacturing of 100million doses by the end of 2020.
A group of pharmaceutical companies, including Japan’s Takeda Pharmaceutical, has begun enrolling patients in a global clinical trial for a potential Wuhan virus treatment using convalescent plasma collected from patients who have recovered from the virus.
The National Institute of Allergy and Infectious Diseases in the US is sponsoring the phase 3 trial, which plans to enroll 500 hospitalised patients in the US, Mexico, and 16 other countries.
Patients who will be treated with the new drug called hyperimmune intravenous immunoglobulin (H-Ig) will also be given Gilead’s antiviral drug Remdesivir, and the results will be compared with those treated with Remdesivir and a placebo.